인플라알엑스 (IFRX) 주가

인플라알엑스(IFRX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.10 (+1.94%), 시가총액 $0.39B, 52주 최저~최고 $0.73 ~ $2.65.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has complet

핵심 지표

• 현재가: $2.10 (+1.94%)
• 시가총액: $0.39B
• 52주 최저~최고: $0.73 ~ $2.65
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

인플라알엑스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

인플라알엑스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.5714

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 8.50
• 순이익률: 0.00%
• 영업이익률: -1447.70%

자주 묻는 질문